Clinical Trials About "Yesner, Boss & Arrighi, P.L." RSS

17:31 EST 11th December 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Yesner, Boss & Arrighi, P.L." on BioPortfolio. We draw our references from global clinical trials data listed on and refresh our database daily.

More Information about "Yesner, Boss & Arrighi, P.L." on BioPortfolio

We have published hundreds of Yesner, Boss & Arrighi, P.L. news stories on BioPortfolio along with dozens of Yesner, Boss & Arrighi, P.L. Clinical Trials and PubMed Articles about Yesner, Boss & Arrighi, P.L. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Yesner, Boss & Arrighi, P.L. Companies in our database. You can also find out about relevant Yesner, Boss & Arrighi, P.L. Drugs and Medications on this site too.

Showing "Yesner Boss Arrighi" Clinical Trials, all 3

Extremely Relevant

The BOSS Study: An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)

The objective of the BOSS Study is to assess acute anatomical and geometric annular and ventricular changes that occur when strategically positioned an external inflatable chambers are applied to the outside of the heart.


Optimization of Blood Pressure Management After Acute Ischemic Stroke and Its Prognostic Significance

BOSS-Trial I is a phase 2 clinical trial with the following objectives; 1. to prove the feasibility of a Bluetooth-equipped sphygmomanometer system in real-world clinical practice and wireless connection to the main server; 2. to prove the feasibility of the BP management strategy, including the pre-specified BP range, BP management algorithm, and behavioral; and 3. to gather information for the phase 3 trial including BP variability indices and their ...

BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection

This study will evaluate the signs and symptoms associated with Fuzeon injection (90mg sc) using the B2000 needle-free injection device, in HIV-1 positive patients experienced to Fuzeon treatment, but having difficulty tolerating long-term (>4 weeks) administration of Fuzeon with the standard needle and syringe. Patients will be randomized to the B2000 device or the standard needle and syringe for 4 weeks; all patients will use the B2000 device for the next 4 weeks. The anticip...

More From BioPortfolio on "Yesner, Boss & Arrighi, P.L."

Quick Search